Gilead Stock News

Ben Emons, Medley Global Advisors, joins Closing Bell to discuss the health care sector and whether now's the time to buy.

New York State Common Retirement Fund decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,437,789 shares of the biopharmaceutical companys stock after selling 79,576 shares during the period. New []

Gilead Sciences Inc (NASDAQ: GILD) announced full results from a Phase 3 study of a three-day course of Veklury (remdesivir) non-hospitalized COVID-19 patients at high risk for disease progression.

(RTTNews) - Gilead Sciences Inc.''s (GILD) veklury or remdesivir significantly reduced risk of hospitalization in high-risk patients with COVID-19, as per results from a phase 3 investigational study. The results have been published in the New England Journal of Medicine and have been submitted to the Food and Drug Administration for the

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced full results from a Phase 3 investigational study evaluating the efficacy and safety of a three-day course of Veklury® (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. The results have been published today in the New England Journal of Medicine (NEJM) and have been submitted to the Food and Drug Administration (FDA) for

Gilead Sciences Inc. (NASDAQ:GILD) traded at $71.88 at last check on Wednesday, December 22, made an upward move of 0.06% on its previous days price. Looking at the stock we see that its previous close was $71.84 and the beta (5Y monthly) reads 0.35 with the days price range being $71.63 $72.59. The company Gilead Sciences Inc.s (NASDAQ:GILD) Stock Is Up 0.06%, But Is It Capable Of A Rally? Read More »

Biden announced very limited set of measured to curb Omicron spread. In my opinion, this won't cut it and it seems likely the hospital system would be overwhelmed without significant further intervent

The FDA has halted all clinical trials testing the injectable form of Gilead''s lenacapavir, for fear that incompatibility between the drug and the vials it''s held in could cause contamination.

This article was originally published on TipRanks.com Gilead Sciences, Inc. The post FDA Puts Gileads Lenacapavir Injection on Clinical Hold appeared first on Smarter Analyst .

Wright Investors Service Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,744 shares of the biopharmaceutical companys stock after acquiring an additional 209 shares during the quarter. Wright Investors []

The FDA has placed a clinical hold on Gilead Sciences Inc''s (NASDAQ: GILD ) injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and pre-exposure prophylaxis (PrEP). The FDA''s clinical hold is due to emerging concerns about the compatibility of borosilicate glass-made vials with lenacapavir solution, which could lead to the formation of sub-visible glass particles in the solution of lenacapavir. The hold will impact ten lenacapavir trials, either monotherapy or combination. Related:

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos''s Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Allakos, Inc. (NASDAQ: ALLK ) announced data from ENIGMA 2 Phase 3 study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis and/or eosinophilic duodenitis and KRYPTOS Phase 2/3 study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis. Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints. The stock was down 7.69% to $77.90 in premarket trading. FDA Imposes Clinical Hold On Injectable Form Of Gilead''s HIV Drug Candidate Due to Concerns Over Vial Quality Gilead Sciences, Inc. (NASDAQ: GILD ) announced that the U.S. Food and Drug Administration has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis.

Nordea Investment Management AB lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 100.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,150,124 shares of the biopharmaceutical companys stock after acquiring an additional 1,076,074 shares during the period. Nordea []